Università della Svizzera italiana

Marine anticancer agents : an overview with a particular focus on their chemical classes

Barreca, Marilia ; Spanò, Virginia ; Montalbano, Alessandra ; Cueto, Mercedes ; Díaz Marrero, Ana R. ; Deniz, Irem ; Erdoğan, Ayşegül ; Lukić Bilela, Lada ; Moulin, Corentin ; Taffin-de-Givenchy, Elisabeth ; Spriano, Filippo ; Perale, Giuseppe ; Mehiri, Mohamed ; Rotter, Ana ; Thomas, Olivier P. ; Barraja, Paola ; Gaudêncio, Susana P. ; Bertoni, Francesco

In: Marine drugs, 2020, vol. 18, no. 12, p. 28

The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve different pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from...

Università della Svizzera italiana

The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax

Tarantelli, Chiara ; Gaudio, Eugenio ; Hillmann, Petra ; Spriano, Filippo ; Sartori, Giulio ; Aresu, Luca ; Cascione, Luciano ; Rageot, Denise ; Kwee, Ivo ; Beaufils, Florent ; Zucca, Emanuele ; Stathis, Anastasios ; Wymann, Matthias P. ; Cmiljanovic, Vladimir ; Fabbro, Doriano ; Bertoni, Francesco

In: Cancers, 2019, vol. 11, no. 6, p. 775

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant dual TORC1/2 inhibitor, in 56...